RhumbLine Advisers
ACOR

RhumbLine Advisers’s Acorda Therapeutics ACOR Stock Holding History

RhumbLine Advisers’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,476
Closed -$165K – 3134
2020
Q1 		$165K Buy
1,476
+60
+4% +$11.8K ﹤0.01% 2644
2019
Q4 		$347K Buy
1,416
+155
+12% +$39.1K ﹤0.01% 2525
2019
Q3 		$434K Buy
1,261
+159
+14% +$86.4K ﹤0.01% 2399
2019
Q2 		$1.01M Buy
1,102
+53
+5% +$65.1K ﹤0.01% 2065
2019
Q1 		$1.67M Buy
1,049
+7
+0.7% +$12.6K ﹤0.01% 1813
2018
Q4 		$1.95M Buy
1,042
+181
+21% +$394K ﹤0.01% 1659
2018
Q3 		$2.03M Sell
861
-78
-8% -$241K ﹤0.01% 1652
2018
Q2 		$3.23M Buy
939
+20
+2% +$61.2K 0.01% 1388
2018
Q1 		$2.61M Buy
919
+19
+2% +$56.9K 0.01% 1460
2017
Q4 		$2.32M Buy
900
+123
+16% +$350K ﹤0.01% 1540
2017
Q3 		$2.21M Buy
777
+14
+2% +$36.9K ﹤0.01% 1550
2017
Q2 		$1.8M Sell
763
-7
-0.9% -$13.9K ﹤0.01% 1645
2017
Q1 		$1.94M Buy
770
+218
+39% +$627K ﹤0.01% 1572
2016
Q4 		$1.25M Sell
552
-7
-1% -$16.6K ﹤0.01% 1731
2016
Q3 		$1.4M Buy
559
+10
+2% +$29.8K ﹤0.01% 1634
2016
Q2 		$1.68M Buy
549
+64
+13% +$208K 0.01% 1459
2016
Q1 		$1.54M Buy
485
+21
+5% +$87.2K ﹤0.01% 1546
2015
Q4 		$2.38M Buy
464
+26
+6% +$114K 0.01% 1239
2015
Q3 		$1.39M Sell
438
-2
-0.5% -$7.76K ﹤0.01% 1569
2015
Q2 		$1.76M Buy
440
+15
+4% +$57.9K 0.01% 1502
2015
Q1 		$1.7M Buy
425
+37
+10% +$169K ﹤0.01% 1516
2014
Q4 		$1.9M Sell
388
-15
-4% -$64.4K 0.01% 1390
2014
Q3 		$1.64M Sell
403
-11
-3% -$41.3K ﹤0.01% 1463
2014
Q2 		$1.68M Sell
414
-2
-0.5% -$8.15K ﹤0.01% 1501
2014
Q1 		$1.89M Sell
416
-2
-0.5% -$8.09K 0.01% 1382
2013
Q4 		$1.47M Sell
418
-36
-8% -$140K ﹤0.01% 1560
2013
Q3 		$1.87M Buy
454
+21
+5% +$90.5K 0.01% 1394
2013
Q2 		$1.71M Buy
+433
New +$1.78M 0.01% 1422

Other funds holding ACOR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RhumbLine Advisers's ACOR Position: Q2 2020 in Review

RhumbLine Advisers sold out of Acorda Therapeutics (ACOR) in Q2 2020, closing a stake of 1,476 shares — an estimated $165K sold.

RhumbLine Advisers first reported a position in ACOR in Q2 2013 and held it in 28 quarters. The position peaked at $3.23M in Q2 2018. 79 funds tracked by Wall St. Rank hold ACOR as of Q2 2020.

  • RhumbLine Advisers reported no remaining Acorda Therapeutics position as of Q2 2020 after selling out during the quarter.
  • RhumbLine Advisers sold 1,476 Acorda Therapeutics shares in Q2 2020, an estimated $165K.
  • RhumbLine Advisers first reported a position in Acorda Therapeutics in Q2 2013 and held it in 28 quarters.
  • RhumbLine Advisers's Acorda Therapeutics position peaked at $3.23M in Q2 2018.
  • 79 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2020.

Based on RhumbLine Advisers's 13F filing for Q2 2020, filed 13 Aug 2020.